Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

• Published in: Annals of oncology Vol. 26; no. 12; pp. 2375 - 2391
• Main Authors: Naidoo, J., Page, D.B., Li, B.T., Connell, L.C., Schindler, K., Lacouture, M.E., Postow, M.A., Wolchok, J.D.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.12.2015; Oxford University Press
• Subjects: adverse event; Animals; anti-PD-1; anti-PD-L1; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - pharmacology; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; Exanthema - chemically induced; Fatigue - chemically induced; Humans; immune checkpoint antibody; Neoplasms - drug therapy; Neoplasms - immunology; Pneumonia - chemically induced; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - immunology; Reviews; toxicity; anti-PD-L1; toxicity; adverse event; immune checkpoint antibody; anti-PD-1

Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-L1 pathway have demonstrated antitumor activity across multiple malignancies, and gained recent regulatory approval as single-agent therapy for the treatment of metastatic malignant melanoma and nonsmall-cell lun...